Hot Logistics Companies For 2017

American Express (AXP) is stuck between a rock and a hard place. As it battles MasterCard (MA) and Visa (V), American Express can either try to match their rewards–which will damage its returns–or stand its ground, which will make it hard to compete. Evercore ISI’s David Togut and team explain:

Getty Images

Credit card rewards continue to spiral skywards asAmerican Express battles Visa- and MasterCard-issuing banks for the mass affluent consumer. Unfortunately for American Express, Chase’s Sapphire Reserve card and Citi’s Prestige card offer superior rewards compared to American Express’s Platinum card, particularly Chase’s 100,000 bonus point sign-up offering. Rich bonus point offerings from the Sapphire Reserve card should negatively pressure American Express’s premium card account acquisition growth, we believe. If rewards competition continues to escalate, so too will the price of growth for American Express, necessitating more aggressive reduction of non-core expenses, of earnings guidance, or both.

Hot Logistics Companies For 2017: Aon Corporation(AON)

Aon Corporation provides risk management services, insurance and reinsurance brokerage, and human resource consulting and outsourcing services primarily in the United States, the Americas, the United Kingdom, Europe, the Middle East, Africa, and the Asia Pacific. The company?s Risk Solutions segment offers retail brokerage products and services, including affinity products, general underwriting management services, placement services, and captive management services; and advisory services to technology, financial services, agribusiness, aviation, construction, health care, and energy industries, as well as facilitates various risk management solutions for property liability, general liability, professional liability, directors’ and officers’ liability, workers’ compensation, and various healthcare products. This segment also provides risk consulting services comprising captive management; eSolutions products that enable clients to manage risks, policies, claims, and safet y concerns through an integrated technology platform; reinsurance brokerage services, such as actuarial, enterprise risk management, catastrophe management, and rating agency advisory services; property and casualty reinsurance; and specialty lines, which include professional liability, medical malpractice, accident, life, and health, as well as capital management transaction and advisory services. Its HR Solutions segment offers human capital services in the areas of health and benefits, retirement, compensation, and strategic human capital; and benefits administration and human resource business process outsourcing services. The company was founded in 1919 and is headquartered in Chicago, Illinois.

Advisors’ Opinion:

  • [By Reuters]

    Wendy Maeda/The Boston Globe via Getty Images NEW YORK — Walgreen is moving 120,000 employees to a private health insurance exchange from coverage provided directly from carriers, the company will announce Wednesday. The pharmacy chain will join 17 other large employers on the Aon Hewitt Corporate Health Exchange as part of a growing movement to offer employees fixed dollar amounts to purchase their own plans on such exchanges. The end-cost to employees depends on the plan chosen, but they typically get more options than under traditional arrangements. Private exchanges mimic the coverage mandated as part of the Affordable Care Act. Enrollment in the public exchanges starts Oct. 1. “What happens to employer contributions over time? Will they put in as much as they put in the past? These are unanswered questions but potential negatives,” says Paul Fronstin, a senior research associate with the Employee Benefit Research Institute. The benefit to Walgreen and other employers is unknown at this point, as their cost-savings aren’t clear. Of the 180,000 Walgreen (WAG) employees eligible for health care insurance, 120,000 opted for coverage for themselves and 40,000 family members. Another 60,000 employees, many of them working part-time, weren’t eligible for health insurance. Aon Hewitt (AON) says other participants in its program include retailer Sears Holding (SHLD) and Darden Restaurants (DRI). These new additions raise enrollment to 330,000 from 100,000 last year, and Aon Hewitt estimates enrollment will jump to 600,000 next year, a fivefold increase from 2012. By 2017, nearly 20 percent of employees nationwide could get their health insurance through a private exchange, according to Accenture Research (ACN). A recent report by the National Business Group on Health said that 30 percent of large employers are considering moving active employees to exchanges by 2015. Other major providers of private exchanges include Mercer, a division of Marsh & Mc

  • [By Javier Hasse]

    In other news, Aon plc Class A Ordinary Shares (UK) (NYSE: AON) boosted its quarterly dividend from $0.30 per share to $0.33 per share, and McGraw Hill Financial Inc (NYSE: MHFI) said it would sell its unit J.D. Power to investment firm XIO Group for $1.1 billion.

Hot Logistics Companies For 2017: Rockwell Collins, Inc.(COL)

 

Rockwell Collins, Inc. designs, produces, and supports communications and aviation systems worldwide. The company operates through three segments: Commercial Systems, Government Systems, and Information Management Services. The Commercial Systems segment provides communications, navigation, and situational awareness and surveillance systems and products, as well as integrated avionics and cabin electronics, electro-mechanical, and simulation and training systems. It also offers satellite-based global voice and data communication products and services; wireless information distribution technologies; and maintenance, repairs, parts, after-sales support services, and aftermarket used equipment. This segment serves original equipment manufacturers of commercial air transport, business and regional aircraft, commercial airlines, and business aircraft operators. The Government Systems segment provides defense-related systems, produc ts, and services comprising communications systems and products; avionics sub-systems; precision targeting, electronic warfare, and range and training systems; and visual system products, and training systems and services. This segment serves U.S. Department of Defense, other ministries of defense, other government agencies, and defense contractors. The Information Management Services segment offers voice and data communication services; flight support services; airport communications and information systems; train dispatching and information systems; mission critical security systems; and backup communications services. This segment serves commercial airlines, business aircraft operators, the U.S. Federal Aviation Administration, airport and critical infrastructure operators, and passenger and freight railroads. The company markets its products directly to customers, as well as through sales force, dealers, and sales representatives. Rockwell Collins, Inc. was founded in 19 33 and is headquartered in Cedar Rapids, Iowa.

Advisors’ Opinion:

  • [By Ben Levisohn]

    Rockwell Collins (COL) has fallen 2.6% to $68.21 after it was downgraded to Neutral from Outperform at Credit Suisse.

    General Electric (GE) has gained 1% to $24.25 after signing a bunch of deals and getting a positive mention from my colleague Jack Hough in this weekend’s Barron’s.

  • [By Ben Levisohn]

    Of the 21 stocks Walton covers, he Buy ratings on eight, including Boeing (BA), Northrop Grumman (NOC), and Rockwell Collins (COL).

    Shares of General Dynamics have dropped 4% to $129 at 2:34 p.m. today, while Boeing has fallen 1.1% to $131.43, Northrop Grumman has declined 0.6% to $193.89, and Rockwell Collins has 0.9% $90.83.

  • [By Lu Wang]

    Rockwell Collins (COL) sank 4.9 percent to $70.61. The maker of airplane cockpit instruments forecast revenue in fiscal 2014 will be no more than $4.60 billion. That missed the average analyst estimate of $4.93 billion in a Bloomberg survey.

Top Construction Stocks To Own For 2017: Chiasma, Inc.(CHMA)

Chiasma, Inc., incorporated on April 12, 2001, is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion.

The Company’s TPE technology enhances the absorption through the intestinal wall of drugs. Using its TPE technology, the Company can transiently and reversibly open the so-called tight junctions between the cells lining the inner intestinal wall, enabling drug molecules to be absorbed intact. Its TPE formulation is a suspension of water-soluble particles containing a precise combination of medium-chain fatty acid salts and drug substance in a fat-soluble medium. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company has initiated a Phase III multi-center, open-label, baseline-controlled clinical trial to evaluate the safety and efficacy of octreotide capsules in patients with acromegaly who responded to and tolerated treatment with somatostatin analogs. The Company also focuses on developing CH2 for Orphan indication.

Advisors’ Opinion:

  • [By Lisa Levin]

    Chiasma Inc (NASDAQ: CHMA) was down, falling around 13 percent to $9.51 ahead of the U.S. Food and Drug Administration’s decision on Friday to approve or reject the company’s therapy. The status of its oral treatment for acromegaly, a capsule known as Mycapssa, will be in focus on Friday. The Street’s biotechnology expert Adam Feuerstein stated that an investor source believes the FDA will reject Chiasma’s capsules because data from a single-arm study failed to demonstrate a clinically meaningful benefit among patients.